The Form 4 filing was submitted on November 18, 2026, one day after the sale. This SEC form reports changes in an insider's stock ownership. Christopher Hite serves as Royalty Pharma's executive vice president and chairman of partnering.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 100,000 |
| Price | $68.15 |
| Total Transaction Value | $6,814,710.00 |
| Insider | |
| Ticker Symbol | RPRX |
| Company | Royalty Pharma plc |
| Insider Name | Hite Christopher |
| Insider Title | EVP & Chairman, Partnering |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 177,523 |
| Position Size Change | 36.03% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of RPRX shares, reported under SEC transaction code S. The filing lists one sale transaction.
What was the average price of the transaction?
The average sale price was $68.1471 per share. That rounds to $68.15, the price shown in the transaction details.
How did this transaction affect the insider's holdings?
The sale reduced the reported holdings by 100,000 shares, leaving 177,523 shares owned afterward. The shares sold made up 36.03% of the 277,523 shares held before the sale. These figures describe the reported share balance, rather than all assets the insider may own.
What's the total transaction value?
The total value of the single sale was $6,814,710.00 when rounded to cents.
Are there any special circumstances around this transaction?
The available information includes a Rule 10b5-1 trading plan reference. These plans set trading instructions in advance. No footnote text was available to confirm whether the reference covers this sale specifically or the filing as a whole. The plan's start date and trading schedule are unknown.
For research purposes only; not investment advice.